Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas

BACKGROUND: Dopamine agonists (DAs) are the first-line treatment for prolactinomas, which account for 25–30% of functioning pituitary adenomas, and bromocriptine (BRC) is the only commercially available DAs in China. However, tumors are resistant to therapy in 5–18% of patients. METHODS: The exomes...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Cancer
Main Authors: Gao, Hua, Wang, Fei, Lan, Xiaolei, Li, Chuzhong, Feng, Jie, Bai, Jiwei, Cao, Lei, Gui, Songbai, Hong, Lichuan, Zhang, Yazhuo
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2015
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4407330/
https://ncbi.nlm.nih.gov/pubmed/25884948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1267-0
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki